EpiVax receives grant to develop diabetes treatment
This article was originally published in Scrip
EpiVax has received a $600,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institutes of Health. The grant, which EpiVax will receive over two years, will be used to develop and reach proof-of-principle for Epi-13, a novel therapeutic for the prevention and treatment of type 1 diabetes. The product targets and reduces undesirable immune responses and has the potential to generate or restore immune regulation in type 1 diabetes. EpiVax received $400,000 from the Juvenile Diabetes Research Foundation in October last year to help the company continue its work on Epi-13. With the NIDDK funding, the company expects to consider trials for the treatment of juvenile diabetes in two to three years. EpiVax's research programme will be carried out in collaboration with Dr David Scott of the University of Maryland and Dr Robert Smith of the Hallet Center for Diabetes and Endocrinology at Rhode Island Hospital.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.